文献速递MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

短端粒长度预测骨髓增生异常综合征干细胞移植后的非复发死亡率

Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome.
PubMed 文献 · Blood · 2020-01-01

该研究在1514例MDS患者移植前血样中测量相对端粒长度,发现最短四分位端粒长度与≥40岁患者更差生存相关,主要因非复发死亡率升高,且该效应限于接受更强预处理方案者。

要点

  • 短端粒与高龄、男性、DNA损伤反应相关体细胞突变及更严重移植前血细胞减少相关。
  • ≥40岁患者中,最短四分位端粒长度与更差生存及更高非复发死亡率独立相关。
  • 短端粒对非复发死亡率的不良影响多见于接受清髓性或更高剂量美法仑降低强度预处理者。

核心结论

  • 短端粒长度可识别MDS移植后因毒性导致生存更差的高危患者。

研究设计与样本

  • 在1514例MDS患者移植前血样中测量相对端粒长度,分析其与疾病特征及移植结局的关联。

主要发现

  • 短端粒长度与高龄、男性、损害DNA损伤反应的体细胞突变及更严重移植前血细胞减少显著相关。
  • 短端粒长度与骨髓原始细胞计数、MDS治疗史或既往癌症治疗史无关。
  • 1267例≥40岁患者中,最短四分位端粒长度与更差生存相关(P < .001),因非复发死亡率高风险(P = .001)。
  • 短端粒对非复发死亡率的影响独立于受体合并症,且选择性见于接受更强预处理方案者。
  • 短端粒对非复发死亡率的影响在发生严重急性移植物抗宿主病患者中突出。

临床怎么用

  • 对短端粒MDS患者可考虑采用聚焦于减少移植毒性的策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic hematopoietic stem cell transplantation is the only potentially curative treatment for patients with myelodysplastic syndrome (MDS), but long-term survival is limited by the risk of transplant-related complications. Short telomere length, mediated by inherited or acquired factors, impairs cellular response to genotoxic and replicative stress and could identify patients at higher risk for toxicity after transplantation. We measured relative telomere length in pretransplant recipient blood samples in 1514 MDS patients and evaluated the association of telomere length with MDS disease characteristics and transplantation outcomes. Shorter telomere length was significantly associated with older age, male sex, somatic mutations that impair the DNA damage response, and more severe pretransplant cytopenias, but not with bone marrow blast count, MDS treatment history, or history of prior cancer therapy. Among 1267 patients ≥40 years old, telomere length in the shortest quartile was associated with inferior survival (P < .001) because of a high risk of nonrelapse mortality (NRM; P = .001) after adjusting for significant clinical and genetic variables. The adverse impact of shorter telomeres on NRM was independent of recipient comorbidities and was observed selectively among patients receiving more intensive conditioning, including myeloablative regimens and higher dose melphalan-based reduced-intensity regimens. The effect of shorter telomeres on NRM was prominent among patients who developed severe acute graft-versus-host disease, suggesting that short telomere length may limit regenerative potential of mucosal tissues after acute injury. MDS patients with shorter telomere length, who have inferior survival driven by excess toxicity, could be considered for strategies focused on minimizing toxic effects of transplantation.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Myllymäki M, Redd R, Reilly CR, et al. Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome. Blood. 2020. PMID: 33367544. doi:10.1182/blood.2020005397

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。